hMENA isoforms impact NSCLC patient outcome through fibronectin/ÎČ1 integrin axis
Di Modugno F, Spada S, Palermo B, Visca P, Iapicca P, Di Carlo A, Antoniani B, Sperduti I, Di Benedetto A, Terrenato I, Mottolese M, Gandolfi F, Facciolo F, Chen EI, Schwartz MA, Santoni A, Bissell MJ, NisticĂČ P. hMENA isoforms impact NSCLC patient outcome through fibronectin/ÎČ1 integrin axis. Oncogene 2018, 37: 5605-5617. PMID: 29907768, PMCID: PMC6193944, DOI: 10.1038/s41388-018-0364-3.Peer-Reviewed Original ResearchConceptsCell lung cancer patientsNSCLC patient outcomeFavorable clinical outcomeLung cancer patientsMechanism of actionClinical outcomesCancer patientsStromal fibronectinClinical managementTranscription factor 1Patient outcomesPatient riskÎ1 integrin expressionIntegrin axisNuclear expressionIntegrin expressionCell invasivenessCancer cellsFibronectin productionExtracellular matrix componentsFactor 1G-actin/F-actin ratioÎ1 integrin activationÎ1 integrin ligandsHMena